Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03158142 · ClinicalTrials.gov registry record · Phase 4
The Influence of Atropine on Choroidal Thickness
A Phase 4 study of Myopia, sponsored by State University of New York College of Optometry.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT03158142: Completed Phase 4 study of Myopia, sponsored by State University of New York College of Optometry.
NCT03158142 is a Phase 4 study of Myopia that has completed, run by State University of New York College of Optometry. The registered enrollment target is 32 participants, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03158142, a Phase 4 study of Myopia, has completed, sponsored by State University of New York College of Optometry.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Atropine eye drops are increasingly prescribed for the management of progressive myopia or short-sightedness. A previous study suggested that the back of the eye or choroid may be a part of the mechanism by which it induces its effects. The aim of this study is to characterize the effects of atropine on choroidal thickness and the influence of time of administration (am vs pm). It is hypothesized that the atropine's effect on choroidal thickness will vary with baseline thickness related to diurnal rhythm, where thicker baseline thickness will show a reduced choroidal response.
Primary Outcome
Change in choroidal thickness after atropine
Conditions Studied
Interventions
- DRUG Atropine Sulfate 1% Oph Soln
Study Locations (1)
New York
- State University of New York College of Optometry - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2017-11-20 |
| Phase | Phase 4 |
What the finished NCT03158142 record still lists
NCT03158142 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 1 intervention - of which Atropine Sulfate 1% Oph Soln is the first listed.
NCT03158142 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03158142 about?
NCT03158142 is a clinical study titled "The Influence of Atropine on Choroidal Thickness". Atropine eye drops are increasingly prescribed for the management of progressive myopia or short-sightedness. A previous study suggested that the back of the eye or choroid may be a part of the mechanism by which it induces its effects. The aim of this study is to characterize the effects of atropi...
What is the current status of trial NCT03158142?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2017-03-15. Estimated completion is 2017-11-20.
What conditions does trial NCT03158142 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT03158142?
The interventions under investigation include: Atropine Sulfate 1% Oph Soln (DRUG).
Who is sponsoring clinical trial NCT03158142?
This trial is sponsored by State University of New York College of Optometry, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03158142 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03158142's enrollment target sits among peer trials
32 84th of 90 higher than 7 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Changes in Eye Shape With Myopia Management Interventions
ACTIVE NOT RECRUITING · Phase 4
-
Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK
COMPLETED · Phase 4
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Clinical Evaluation of WaveLight Plus LASIK
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI